MedImmune LLC $AZN
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING0
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +7.8 months). See all sponsors →
Open MedImmune LLC on the live radar map → 📅 $AZN readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Tremelimumab NCT01843374 |
P2 | Active, not recruiting | Unresectable Pleural or Peritoneal Malignant Mesothelioma | 571 | 2016-01-24 (+8 mo) |
| Tremelimumab NCT02519348 |
P2 | Active, not recruiting | Hepatocellular Carcinoma | 433 | 2020-11-06 (+20 mo) |
| Oleclumab NCT03381274 |
P1/2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 43 | 2021-05-24 (-6 mo) |
| Monalizumab NCT02671435 |
P1/2 | Active, not recruiting | Advanced Solid Tumors | 383 | 2021-10-26 (+23 mo) |
| Durvalumab NCT04068610 |
P1/2 | Active, not recruiting | Metastatic Microsatellite-stable Colorectal Cancer | 61 | 2022-10-10 (-16 mo) |